You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

rituximab

Showing 51 - 75 of 2,665
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rheumatic Heart Disease in Children Trial (Rituximab added to standard of care treatment, standard of care treatment)

Not yet recruiting
  • Rheumatic Heart Disease in Children
  • Rituximab added to standard of care treatment
  • standard of care treatment
  • (no location specified)
Jan 3, 2023

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS Trial in Amsterdam

Recruiting
  • Multiple Sclerosis
  • +5 more
  • Rituximab
  • Amsterdam, Netherlands
    Amsterdam UMC, location VUmc
Apr 17, 2023

Steroid-Sensitive Nephrotic Syndrome Trial in Shanghai (Rituximab, Corticosteroid)

Not yet recruiting
  • Steroid-Sensitive Nephrotic Syndrome
  • Shanghai, Shanghai, China
  • +2 more
May 6, 2023

Large B-Cell Lymphoma Trial in Xi'an (Glofitamab, Polatuzumab vedotin, Rituximab)

Not yet recruiting
  • Large B-Cell Lymphoma
  • Xi'an, China
    First Affiliated Hospital of Medical College of Xi'an Jiaotong U
Sep 14, 2023

Rheumatoid Arthritis Trial in Belgium (Rituximab)

Not yet recruiting
  • Rheumatoid Arthritis
  • Rituximab
  • Merksem, Antwerpen, Belgium
  • +6 more
Aug 17, 2023

Nephrotic Syndrome, Proteinuria, Autoimmune Disease Trial run by the NIDDK (Rituximab Infusion, Oral Cyclosporine)

Recruiting
  • Nephrotic Syndrome
  • +4 more
  • Rituximab Infusion
  • Oral Cyclosporine
  • Bethesda, Maryland
  • +1 more
Jan 25, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Leukemia
  • (no location specified)
Nov 30, 2022

APS Secondary to SLE

Recruiting
  • Antiphospholipid Syndrome
  • Jinan, Shandong, China
    Qilu Hospital
Nov 30, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Pharmacological Action Trial (Rituximab, Dexamethasone)

Not yet recruiting
  • Pharmacological Action
  • (no location specified)
Sep 22, 2022

Schizophrenia Spectrum and Other Psychotic Disorders Trial in Örebro (Rituximab)

Not yet recruiting
  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Rituximab
  • Örebro, Sweden
    Örebro university hospital
Nov 21, 2022

Follicular Lymphoma Trial in Australia (Opdivo)

Active, not recruiting
  • Follicular Lymphoma
  • Ballarat, Victoria, Australia
  • +4 more
Jan 30, 2023

Hairy Cell Leukemia Trial run by the NCI (Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience)

Active, not recruiting
  • Hairy Cell Leukemia
  • Moxetumomab Pasudotox-tdfk
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Follicular Lymphoma Trial (Bendamustine, Rituximab, Tazemetostat)

Not yet recruiting
  • Follicular Lymphoma
  • (no location specified)
Dec 15, 2022

Nephrotic Syndrome Steroid-Dependent Trial in Genova (Rituximab Biosimilar)

Recruiting
  • Nephrotic Syndrome Steroid-Dependent
  • Rituximab Biosimilar
  • Genova, Italy
    IRCCS G. Gaslini
Dec 19, 2022

Lymphoma Trial in Houston (Rituximab, Lenalidomide, Valemetostat)

Not yet recruiting
  • Lymphoma
  • Rituximab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 4, 2023

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Rituximab in Children With Blood Diseases

Not yet recruiting
  • Rituximab
  • +2 more
  • Rituximab
  • Rituximab (once a week)
  • (no location specified)
Apr 8, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Diffuse Large B-cell Lymphoma Trial in Shanghai (Rituximab, Cyclophosphamide, Epirubicin)

Active, not recruiting
  • Diffuse Large B-cell Lymphoma
  • Rituximab
  • +4 more
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
Dec 1, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

IgA Nephropathy Trial in Shanghai (rituximab group)

Active, not recruiting
  • IgA Nephropathy
  • rituximab group
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Apr 9, 2023

Waldenstrom's Macroglobulinemia Trial in Houston (Bortezomib, Rituximab, Valacyclovir)

Active, not recruiting
Has Results
  • Waldenstrom's Macroglobulinemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 5, 2022

Follicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV Trial in Australia (BMS-986369,

Not yet recruiting
  • Follicular Lymphoma Stage II
  • +2 more
  • Ballarat, Victoria, Australia
  • +4 more
Mar 15, 2023